Federal Register / Vol. 79, No. 236 / Tuesday, December 9, 2014 / Notices 73087 

Oral presentations from the public will 

be scheduled between approximately 1 

p.m. and 2 p.m. Those individuals 

interested in making formal oral 

presentations should notify the contact 

person and submit a brief statement of 

the general nature of the evidence or 

arguments they wish to present, the 

names and addresses of proposed 

participants, and an indication of the 

approximate time requested to make 

their presentation on or before 

December 17, 2014. Time allotted for 

each presentation may be limited. If the 

number of registrants requesting to 

speak is greater than can be reasonably 

accommodated during the scheduled 

open public hearing session, FDA may 

conduct a lottery to determine the 

speakers for the scheduled open public 

hearing session. The contact person will 

notify interested persons regarding their 

request to speak by December 18, 2014. 

Persons attending FDA’s advisory 

committee meetings are advised that the 

Agency is not responsible for providing 

access to electrical outlets. 

FDA welcomes the attendance of the 

public at its advisory committee 

meetings and will make every effort to 

accommodate persons with physical 

disabilities or special needs. If you 

require special accommodations due to 

a disability, please contact Stephanie L. 

Begansky (see Contact Person) at least 7 

days in advance of the meeting. 

FDA is committed to the orderly 

conduct of its advisory committee 

meetings. Please visit our Web site at 

http://www.fda.gov/

AdvisoryCommittees/

AboutAdvisoryCommittees/

ucm111462.htm for procedures on 

public conduct during advisory 

committee meetings. 

Notice of this meeting is given under 

the Federal Advisory Committee Act (5 

U.S.C. app. 2). 

Dated: December 2, 2014. 

Jill Hartzler Warner, 

Associate Commissioner for Special Medical 

Programs. 

[FR Doc. 2014–28702 Filed 12–8–14; 8:45 am] 

BILLING CODE 4164–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Office of the Director Notice of Charter 

Renewal 

In accordance with Title 41 of the 

U.S. Code of Federal Regulations, 

Section 102–3.65(a), notice is hereby 

given that the Charter for the Board of 

Regents of the National Library of 

Medicine (BOR) was renewed for an 

additional two-year period on 

November 20, 2014. 

It is determined that the BOR is in the 

public interest in connection with the 

performance of duties imposed on the 

Department of Health and Human 

Services by law, and that these duties 

can best be performed through the 

advice and counsel of this group. 

Inquires may be directed to Jennifer S. 

Spaeth, Director, Office of Federal 

Advisory Committee Policy, Office of 

the Director, National Institutes of 

Health, 6701 Democracy Boulevard, 

Suite 1000, Bethesda, Maryland 20892 

(Mail Code 4875), Telephone (301) 496– 

2123, or spaethj@od.nih.gov. 

Dated: December 3, 2014. 

Jennifer S. Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2014–28750 Filed 12–8–14; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Government-Owned Inventions; 

Availability for Licensing 

AGENCY: National Institutes of Health, 

HHS. 

ACTION: Notice. 

SUMMARY: The inventions listed below 

are owned by an agency of the U.S. 

Government and are available for 

licensing in the U.S. in accordance with 

35 U.S.C. 209 and 37 CFR part 404 to 

achieve expeditious commercialization 

of results of federally-funded research 

and development. Foreign patent 

applications are filed on selected 

inventions to extend market coverage 

for companies and may also be available 

for licensing. 

FOR FURTHER INFORMATION CONTACT: 

Licensing information and copies of the 

U.S. patent applications listed below 

may be obtained by writing to the 

indicated licensing contact at the Office 

of Technology Transfer, National 

Institutes of Health, 6011 Executive 

Boulevard, Suite 325, Rockville, 

Maryland 20852–3804; telephone: 301– 

496–7057; fax: 301–402–0220. A signed 

Confidential Disclosure Agreement will 

be required to receive copies of the 

patent applications. 

SUPPLEMENTARY INFORMATION: 

Technology descriptions follow. 

Vaccine for Protection Against 

Shigella sonnei Disease 

Description of Technology: 

Shigellosis is a global human health 

problem. Transmission usually occurs 

by contaminated food and water or 

through person-to-person contact. The 

bacterium is highly infectious by the 

oral route, and ingestion of as few as 10 

organisms can cause an infection in 

volunteers. An estimated 200 million 

people worldwide suffer from 

shigellosis, with more than 650,000 

associated deaths annually. A recent 

CDC estimate indicates the occurrence 

of over 440,000 annual shigellosis cases 

in the United States alone, 

approximately eighty percent (80%) of 

which are caused by Shigella sonnei. 

Shigella sonnei is more active in 

developed countries. Shigella infections 

are typically treated with a course of 

antibiotics. However, due to the 

emergence of multidrug resistant 

Shigella strains, a safe and effective 

vaccine is highly desirable. No vaccines 

against Shigella infection currently 

exist. Immunity to Shigellae is mediated 

largely by immune responses directed 

against the serotype specific Opolysaccharide. Claimed in the 

invention are compositions and 

methods for inducing an 

immunoprotective response against S. 

sonnei. Specifically, an attenuated 

bacteria capable of expressing an S. 

sonnei antigen comprised of the S. 

sonnei form I O-polysaccharide 

expressed from the S. sonnei rfb/rfc 

gene cluster is claimed. The inventors 

have shown that the claimed vaccine 

compositions showed one hundred 

percent (100%) protection against 

parenteral challenge with virulent S. 

sonnei in mice. 

Potential Commercial Applications: 

• Shigella/Typhoid vaccine for 

travelers, military 

• Shigella/Typhoid vaccine for 

developing countries 

• Shigella/Typhoid diagnostics 

Competitive Advantages: 

• Low cost of production 

• Temperature stable formulation 

• Safety/efficacy of Ty21a established 

in humans 

Development Stage: In vivo data 

available (animal) 

Inventors: Dennis J. Kopecko (FDA), 

De Qi Xu (NIDCR), John O. Cisar 

(NICHD) 

Publication: Kopecko DJ, et al. 

Molecular cloning and characterization 

of genes for Shigella sonnei form I O 

polysaccharide: proposed biosynthetic 

pathway and stable expression in a live 

salmonella vaccine vector. Infect 

Immun. 2002 Aug;70(8):4414–23. 

[PMID: 12117952] 


rljohnson on DSK3VPTVN1PROD with NOTICES
73088 Federal Register / Vol. 79, No. 236 / Tuesday, December 9, 2014 / Notices 

Intellectual Property: HHS Reference 

No. E–210–2001/0 – 

• US Patent No. 7,541,043 issued 02 

Jun 2009 

• US Patent No. 8,071,084 issued 06 

Dec 2011 

• US Patent No. 8,337,832 issued 25 

Dec 2012 

• US Patent Application No. 13/

686,299 filed 27 Nov 2012 

Licensing Contact: Peter A. Soukas; 

301–435–4646; soukasp@mail/nih.gov 

Live Oral Shigella dysenteriae 

Vaccine 

Description of Technology: This 

application claims a Salmonella typhi 

Ty21a construct comprising a Shigella 

dysenteriae O-specific polysaccharide 

(O-Ps) inserted into the Salmonella 

typhi Ty21a chromosome, where 

heterologous Shigella dysenteriae 

serotype 1 O-antigen is stably expressed 

together with homologous Salmonella 

typhi O-antigen. The constructs of this 

invention elicit immune protection 

against virulent Shigella dysenteriae 

challenge, as well as Salmonella typhi 

challenge. Also claimed in this 

application are methods of making the 

constructs of this invention and 

methods for inducing an immune 

response. 

Shigella cause millions of cases of 

dysentery every year, which result in 

about seven hundred thousand deaths 

worldwide. Shigella dysenteriae 

serotype 1, one of about forty serotypes 

of Shigella, causes a more severe disease 

with a much higher mortality rate than 

other serotypes. There are no licensed 

vaccines available for protection against 

Shigella. The fact that many isolates 

exhibit multiple antibiotic resistance 

complicates the management of 

dysentery infections. 

Potential Commercial Applications: 

• One component of a multivalent 

anti-shigellosis vaccine under 

development. 

• Shigella vaccines, therapeutics and 

diagnostics. 

Competitive Advantages: 

• Vector is well-characterized. 

• Simple manufacturing process. 

• Potential low-cost vaccine. 

• Oral vaccine—avoids need for 

needles. 

• Temperature-stable formulation 

allows for vaccine distribution without 

refrigeration. 

Development Stage: 

• In vitro data available 

• In vivo data available (animal) 

Inventors: Dennis J. Kopecko and De 

Qi Xu (FDA/CBER) 

Publication: Xu DQ, et al. Core-linked 

LPS expression of Shigella dysenteriae 

serotype 1 O-antigen in live Salmonella 

typhi vaccine vector Ty21a: Preclinical 

evidence of immunogenicity and 

protection. Vaccine. 2007 Aug 

14;25(33):6167–75. [PMID 17629369] 

Intellectual Property: HHS Reference 

No. E–214–2004/0 - 

• US Patent No. 8,071,113 issued 06 

Dec 2011 

• US Patent No. 8,337,831 issued 25 

Dec 2012 

• US Patent No. 8,790,635 issued 29 

Jul 2014 

• US Patent Application No. 14/ 

145,104 filed 31 Dec 2013 (allowed) 

• Various international patent 

applications pending 

Licensing Contact: Peter A. Soukas; 

301–435–4646; soukasp@mail.nih.gov 

Oral Shigellosis Vaccine 

Description of Technology: This 

application claims a Salmonella typhi 

Ty21a construct comprising a Shigella 

sonnei O-antigen biosynthetic gene 

region inserted into the Salmonella 

typhi Ty21a chromosome, where 

heterologous Shigella sonnei form 1 Oantigen is stably expressed together with 

homologous Salmonella typhi Oantigen. The constructs of this invention 

elicit immune protection against 

virulent Shigella sonnei challenge, as 

well as Salmonella Typhi challenge. 

Also claimed in this application are 

methods of recombineering a large 

antigenic gene region into a bacterial 

chromosome. 

Bacillary dysentery and enteric fevers 

continue to be important causes of 

morbidity in both developed and 

developing nations. Shigella cause 

greater than one hundred and fifty 

million cases of dysentery and enteric 

fever occurs in greater than twentyseven million people annually. 

Currently, there is no licensed vaccine 

to prevent the occurrence of shigellosis. 

Increasing multiple resistance in 

Shigella commonly thwarts local 

therapies. 

Potential Commercial Applications: 

• One component of a multivalent 

Shigellosis vaccine under development 

• Research tool 

Competitive Advantages: 

• Low cost production 

• Lower cost vaccine 

• Oral vaccine—no needles required 

• Temperature-stable manufacturing 

process—avoids need for refrigeration 

during vaccine distribution 

Development Stage: 

• In vitro data available 

• In vivo data available (animal) 

Inventors: Dennis J. Kopecko and 

Madushini N. Dharmasena (FDA/CBER) 

Publication: Dharmasena MN, et al. 

Stable expression of Shigella sonnei 

form I O-polysaccharide genes 

recombineered into the chromosome of 

live Salmonella oral vaccine vector 

Ty21a. Int J Med Microbiol. 2013 

Apr;303(3):105–13. [PMID 23474241] 

Intellectual Property: HHS Reference 

No. E–168–2012/0 - 

• US Provisional Application No. 61/ 

701,939 filed 17 Sep 2012 

• PCT Application No. PCT/US2013/ 

059980 filed 16 Sep 2013, which 

published as WO 2014/043637 on 20 

Mar 2014 

Licensing Contact: Peter A. Soukas; 

301–435–4646; soukasp@mail.nih.gov 

Acid-Resistant, Attenuated Microbial 

Vector for Improved Oral Delivery of 

Multiple Targeted Antigens 

Description of Technology: Ty21a, the 

licensed oral live, attenuated bacterial 

vaccine for Salmonella typhi (the 

causative agent of typhoid fever), has 

been engineered to stably express a 

variety of target LPS 

(lipopolysaccharides) and protein 

antigens to protect against shigellosis, 

anthrax, and plague. Ty21a induces 

mucosal, humoral, and cellular 

immunity and can be utilized as a 

multivalent vaccine vector that is 

inexpensive to produce. Salmonella 

species encode inducible acid tolerance, 

but this genus does not survive well 

below pH 4. Shigella and 

enterohemorrhagic E. coli isolates have 

more effective acid resistance systems 

than Salmonella and can survive an 

extreme acid challenge of pH 1–2 (the 

acidity of the human stomach when 

full). 

This application claims an engineered 

Ty21a vector that can survive a very low 

pH for two to three hours (i.e., normal 

transit time through a full stomach), 

allowing for a final delivery format for 

Ty21a as a rapidly dissolvable wafer, 

instead of the large bullet-size entericcoated capsule, which small children 

cannot swallow. This formulation 

enhances the ability of the 

immunogenic composition and/or 

vaccine to stimulate immune responses 

sublingually and throughout the 

intestinal tract. 

Potential Commercial Applications: 

• Shigella vaccines 

• Biodefense vaccines 

• Diagnostics 

Competitive Advantages: 

• Ease of manufacture 

• Inexpensive to manufacture 

• Ease of administration 

• Known live attenuated bacterial 

vector 

Development Stage: 

• In vitro data available 

• In vivo data available (animal) 

Inventors: Madushini N. Dharmasena 

and Dennis J. Kopecko (FDA/CBER) 


rljohnson on DSK3VPTVN1PROD with NOTICES
Federal Register / Vol. 79, No. 236 / Tuesday, December 9, 2014 / Notices 73089 

Intellectual Property: HHS Reference 

No. E–535–2013/0 - 

• US Provisional Application No. 61/ 

862,815 filed 06 Aug 2013 

• PCT Application No. PCT/US2014/ 

049933 filed 06 Aug 2014 

Licensing Contact: Peter A. Soukas; 

301–435–4646; soukasp@mail.nih.gov 

Attenuated Salmonella as a Delivery 

System for siRNA-Based Tumor 

Therapy 

Description of Technology: This 

technology comprises live, attenuated 

Salmonella strains as a delivery system 

for small interfering double-stranded 

RNA (siRNA)-based tumor therapy. The 

inventors’ data provide the first 

convincing evidence that Salmonella 

can be used for delivering plasmidbased siRNAs into tumors growing in 

vivo. Claimed in the related patent 

application are methods of inhibiting 

the growth or reducing the volume of 

solid cancer tumors using the si-RNA 

constructs directed against genes that 

promote tumor survival and cancer cell 

growth. The Stat3-siRNAs carried by an 

attenuated S. typhimurium described in 

the application exhibit tumor 

suppressive effects not only on the 

growth of the primary tumor but also on 

the development of metastases, 

suggesting that an appropriate 

attenuated S. typhimurium combined 

with the RNA interference (RNAi) 

approach may offer a clinically feasible 

method for cancer therapy. 

Potential Commercial Applications: 

• Development of live attenuated 

bacterial cancer vaccines, cancer 

therapeutics and diagnostics. 

• Developing/developed world 

vaccine. 

Competitive Advantages: 

• Low cost of production 

• Vaccine vector safety/efficacy in 

humans established 

Development Status: In vivo data 

available (animal) 

Inventors: Dennis J. Kopecko (FDA), 

De Qi Xu (FDA), Ling Zhang (Jilin 

University), Xuejian Zhao (Jilin 

University), Jiadi Hu (University of 

Maryland) 

Publications: 

1. Zhang L, et al. Intratumoral 

delivery and suppression of prostate 

tumor growth by attenuated Salmonella 

enterica serovar typhimurium carrying 

plasmid-based small interfering RNAs. 

Cancer Res. 2007 Jun 15;67(12):5859–64. 

[PMID 17575154] 

2. Zhang L, et al. Effects of plasmidbased Stat3-specific short hairpin RNA 

and GRIM–19 on PC–3M tumor cell 

growth. Clin Cancer Res. 2008 Jan 

15;14(2):559–68. [PMID 18223232] 

Intellectual Property: HHS Reference 

No. E–278–2007/0 - 

• PCT Application No. PCT/US2007/ 

074272 filed 27 Jul 2007, which 

published as WO 2008/091375 on 31 Jul 

2008 

• U.S. Patent Application No. 12/ 

374,916 filed 23 Jan 2009 

• International Application No. 

200610017045.5 filed in China 27 Jul 

2006 

Licensing Contact: Peter A. Soukas; 

301–435–4616; soukasp@mail.nih.gov 

DNA Promoters and Anthrax Vaccines 

Description of Technology: Currently, 

the only licensed vaccine against 

anthrax in the United States is AVA 

BioThrax®, which, although efficacious, 

suffers from several limitations. This 

vaccine requires six injectable doses 

over 18 months to stimulate protective 

immunity, requires a cold chain for 

storage, and in many cases has been 

associated with adverse effects. 

This application claims a modified B. 

anthracis protective antigen (PA) gene 

for optimal expression and stability, 

linked it to an inducible promoter for 

maximal expression in the host, and 

fused to the secretion signal of the 

Escherichia coli alpha-hemolysin 

protein (HlyA) on a low-copy-number 

plasmid. This plasmid was introduced 

into the licensed typhoid vaccine strain, 

Salmonella enterica serovar Typhi 

strain Ty21a, and was found to be 

genetically stable. Immunization of mice 

with three vaccine doses elicited a 

strong PA-specific serum 

immunoglobulin G response with a 

geometric mean titer of 30,000 (range, 

5,800 to 157,000) and lethal-toxinneutralizing titers greater than 16,000. 

Vaccinated mice demonstrated 100% 

protection against a lethal intranasal 

challenge with aerosolized spores of B. 

anthracis 7702. 

Potential Commercial Applications: 

Anthrax vaccines, therapeutics and 

diagnostics. 

Competitive Advantages: 

• Vector is well-characterized. 

• Simple manufacturing process. 

• Potential low-cost vaccine. 

• Oral vaccine—avoids needles and 

can be administered rapidly during 

emergencies. 

• Temperature-stable manufacturing 

allows for vaccine distribution without 

refrigeration. 

Development Stage: 

• In vitro data available 

• In vivo data available (animal) 

Inventors: Dennis J. Kopecko, Siba 

Bhattacharyya, Milan Blake (all of FDA/ 

CBER) 

Publication: Osorio M, et al. Anthrax 

protective antigen delivered by 

Salmonella enterica serovar Typhi 

Ty21a protects mice from a lethal 

anthrax spore challenge. Infect Immun. 

2009 Apr;77(4):1475–82. [PMID 

19179420] 

Intellectual Property: HHS Reference 

No. E–344–2003/1 - 

• U.S. Patent No. 7,758,855 issued 20 

Jul 2010 

• U.S. Patent No. 8,247,225 issued 21 

Aug 2012 

• U.S. Patent No. 8,709,813 issued 29 

Apr 2014 

• U.S. Patent Application No. 14/ 

185,353 filed 20 Feb 2014 

• Various international patents issued 

Licensing Contact: Peter A. Soukas; 

301–435–4646; soukasp@mail.nih.gov 

Typhoid-Plague Bivalent Vaccine 

Description of Technology: Yersinia 

pestis (Y. pestis) bacteria is the 

causative agent of plague, typically 

transmitted from animals to humans by 

the bite of an infected flea. Y. pestis 

infection of the lungs leads to 

pneumonic plague, which is highly 

contagious and generally fatal. Y. pestis 

is a potential bioterrorist threat agent for 

which no vaccine yet exists. 

This invention claims the generation 

and development of a candidate oral 

vaccine against plague. The vaccine 

consists of a synthetic gene construct 

that expresses a Y. pestis F1–V fusion 

antigen linked to a secretion signal, 

resulting in the production of large 

amounts of the F1–V antigen. The F1– 

V synthetic gene fusion is housed 

within Ty21a, an attenuated typhoid 

fever strain that is licensed for human 

use as a live oral bacterial vaccine. 

Ty21a serves as a carrier to deliver the 

F1–V fusion antigens of the plague 

bacteria; the combined F1–V fusion in 

the Ty21a carrier has been shown to 

stimulate a robust immune response in 

mice. The possibility of combining the 

oral plague vaccine of this invention 

with FDA’s candidate oral anthrax 

vaccine exists and would result in an 

easy-to-administer oral delivery system 

to streamline administration of the 

vaccine to large numbers of recipients in 

emergency situations. 

Potential Commercial Applications: 

Plague vaccines, therapeutics and 

diagnostics. 

Competitive Advantages: 

• Vector is well-characterized. 

• Simple manufacturing process. 

• Potential low-cost vaccine. 

Development Stage: 

• In vitro data available 

• In vivo data available (animal) 

Inventors: Dennis J. Kopecko, Manuel 

A. Osorio, Monica R. Foote (all of FDA/ 

CBER) 

Intellectual Property: HHS Reference 

No. E–105–2011/0 - 

• U.S. Provisional Application No. 

61/650,676 filed 23 May 2012 


rljohnson on DSK3VPTVN1PROD with NOTICES
73090 Federal Register / Vol. 79, No. 236 / Tuesday, December 9, 2014 / Notices 

• PCT Application No. PCT/US2013/ 

042240 filed 22 May 2013, which 

published as WO 2013/177291 on 28 

Nov 2013 

Related Technologies: HHS Reference 

No. E–344–2003/1- 

• U.S. Patent No. 7,758,855 issued 20 

Jul 2010 

• U.S. Patent No. 8,247,225 issued 21 

Aug 2012 

• U.S. Patent No. 8,709,813 issued 29 

Apr 2014 

• U.S. Patent Application No. 14/ 

185,353 filed 20 Feb 2014 

• Various international patents issued 

Licensing Contact: Peter A. Soukas; 

301–435–4616; soukasp@mail.nih.gov 

Dated: December 3, 2014. 

Richard U. Rodriguez, 

Acting Director, Office of Technology 

Transfer, National Institutes of Health. 

[FR Doc. 2014–28748 Filed 12–8–14; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Center for Scientific Review; Notice of 

Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Program 

Project: AIDS and AIDS Related Research. 

Date: December 15, 2014. 

Time: 10:30 a.m. to 4:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892, 

(Telephone Conference Call). 

Contact Person: Jose H Guerrier, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 5218, 

MSC 7852, Bethesda, MD 20892, 301–435– 

1137, guerriej@csr.nih.gov. 

This notice is being published less than 15 

days prior to the meeting due to the timing 

limitations imposed by the review and 

funding cycle. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Member 

Conflict: AIDS and AIDS Related Research. 

Date: December 15, 2014. 

Time: 2:00 p.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892, 

(Telephone Conference Call). 

Contact Person: Mary Clare Walker, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 5208, 

MSC 7852, Bethesda, MD 20892, (301) 435– 

1165, walkermc@csr.nih.gov. 

This notice is being published less than 15 

days prior to the meeting due to the timing 

limitations imposed by the review and 

funding cycle. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Special 

Topics in HIV/AIDS Behavioral Research. 

Date: December 18, 2014. 

Time: 10:00 a.m. to 1:00 p.m. 

Agenda: To review and evaluate grant 

applications and/or proposals. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892, 

(Telephone Conference Call). 

Contact Person: Mark P Rubert, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 5218, 

MSC 7852, Bethesda, MD 20892, 301–435– 

1775, rubertm@csr.nih.gov. 

This notice is being published less than 15 

days prior to the meeting due to the timing 

limitations imposed by the review and 

funding cycle. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Pathologies 

in the Nervous System. 

Date: December 18, 2014. 

Time: 1:00 p.m. to 3:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892, 

(Telephone Conference Call). 

Contact Person: Peter B Guthrie, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 4142, 

MSC 7850, Bethesda, MD 20892, (301) 435– 

1239, guthriep@csr.nih.gov. 

This notice is being published less than 15 

days prior to the meeting due to the timing 

limitations imposed by the review and 

funding cycle. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.306, Comparative Medicine; 

93.333, Clinical Research, 93.306, 93.333, 

93.337, 93.393–93.396, 93.837–93.844, 

93.846–93.878, 93.892, 93.893, National 

Institutes of Health, HHS) 

Dated: December 3, 2014. 

Michelle Trout, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2014–28752 Filed 12–8–14; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Center for Scientific Review; Notice of 

Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Special 

Topic: Small Business Innovative 

Immunology Research. 

Date: December 18, 2014. 

Time: 3:00 p.m. to 4:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892, 

(Telephone Conference Call). 

Contact Person: Andrea Keane-Myers, BS, 

Ph.D., Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 4218, 

Bethesda, MD 20892, 301–435–1221, 

andrea.keane-myers@nih.gov. 

This notice is being published less than 15 

days prior to the meeting due to the timing 

limitations imposed by the review and 

funding cycle. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.306, Comparative Medicine; 

93.333, Clinical Research, 93.306, 93.333, 

93.337, 93.393–93.396, 93.837–93.844, 

93.846–93.878, 93.892, 93.893, National 

Institutes of Health, HHS) 

Dated: December 3, 2014. 

David Clary, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2014–28747 Filed 12–8–14; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Neurological 

Disorders and Stroke; Notice of Closed 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 


rljohnson on DSK3VPTVN1PROD with NOTICES